The Next Generation of CIRBI, the Technology Powering Advarra’s IRB
A note from Lauri Carlile, Chief Research Services Officer: For more than 40 years, Advarra’s institutional review board (IRB) has
Universal
Q&A with Advarra’s Client Services Team Lead Kyle Naylor
Kyle Naylor didn’t set out to work in the IRB world—but once he found it, he never looked back. Now a team lead supporting
Do DSMBs Need AI Expertise?
Rethinking oversight as clinical trials become more data-driven and algorithm-informed As artificial intelligence (AI) becomes more embedded in clinical trial
London Innovation Summit: Let your network know you’ll be there!
Heading to the Advarra Innovation Summit in London? Share the news and encourage your peers and partners to join you!
Q&A with Advarra’s Manager of Ongoing Review MaryJo Carter
MaryJo Carter has spent more than nine years at Advarra, growing alongside the organization and helping shape how teams show up for
Data Safety Monitoring Boards (DSMBs) in the Era of AI and Adaptive Clinical Trials
Balancing innovation, statistical rigor, and independent oversight in increasingly complex clinical trials Clinical trials are no longer static. Over the
Q&A with Advarra’s Associate Director of Client Success Evan Sander
Evan Sander knows firsthand that clinical research is never just about processes or paperwork—it’s about people. As associate director of
Federal Public Policy Briefing: Understanding 21 CFR 50.54: When FDA-Regulated Pediatric Research Requires Federal Review
Federal Public Policy Briefing: Understanding 21 CFR 50.54: When FDA-Regulated Pediatric Research Requires Federal Review Research involving children that poses
A More Connected Approach to Clinical Trials: Reducing Friction from Study Design Through Conduct
Clinical trials are complex. That’s expected, given accelerated advancements in science and technology. But when that complexity creates friction in
Gene Therapy Is Seen as the Next Big Biologic in Ophthalmology
Over the last 15 to 20 years, monoclonal antibody-based treatments, such as those targeting vascular endothelial growth factor (anti-VEGF), have
Clinical Oncology Advisory Board
Why we exist Oncology research is moving quickly, and study teams face mounting complexity: novel modalities, new data tools, shifting
